Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    9
ATC Name B/G Ingredients Dosage Form Price
J01FA10 ERADECIN G Azithromycin - 250mg 250mg Capsule 354,774 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
D07XC03 ELICASAL G Mometasone furoate - 1mg/g, Salicylic acid - 50mg/g Ointment 462,282 L.L
A11CC05 EURO D HP 50.000 IU G Vitamin D3 - 50,000IU 50,000IU Capsule 1,432,536 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
C03DA04 EPLERENONE ARROW G Eplerenone - 50mg 50mg Tablet, coated 1,744,308 L.L
A02BC05 ESAC G Esomeprazole sodium - 40mg 40mg Injectable powder for solution 430,030 L.L
C03DA04 EPLERENONE BIOGARAN G Eplerenone - 50mg 50mg Tablet, coated 1,849,127 L.L
G04BE03 EREC G Sildenafil - 100mg 100mg Tablet, film coated 792,867 L.L
A02BC05 ESOMEPRAZOLE NORMON G Esomeprazole - 40mg 40mg Injectable powder for solution 430,030 L.L
A02BC05 ESSIUM G Esomeprazole - 40mg 40mg Injectable powder for solution 314,459 L.L
D08AX01 EAU OXYGENEE 10/120 G Hydrogen peroxide - 10V 10V Solution 119,026 L.L
D08AX02 EOSIN ALCOHOLIC G Eosin - 2% 2% Solution 115,187 L.L
L04AX04 ERVALI G Lenalidomide - 10mg 10mg Capsule, hard 71,493,520 L.L
D08AX02 EOSIN AQUEUSE G Eosin - 2% 2% Solution 98,548 L.L
D08AX02 EOSIN ALCOHOLIC G Eosin - 1% 1% Solution 108,787 L.L
D08AX02 EOSIN AQUEUSE G Eosin - 1% 1% Solution 84,470 L.L
N02BE51 EXTRA STRENGTH HEADACHE RELIEF G Acetaminophen - 250mg, Acetylsalicylic acid - 250mg, Caffeine - 65mg Tablet 353,431 L.L
B03AD EURO-FER CF G Folic acid - 0.5mg, Vitamin C - 200mg, Ferrous fumarate - 300mg Capsule 706,861 L.L
G04BE08 ENKOR G Tadalafil - 20mg 20mg Tablet, film coated 1,032,839 L.L
L04AX04 ERVALI G Lenalidomide - 15mg 15mg Capsule, hard 74,977,720 L.L
B03AE02 ELEVIT PRONATAL G Vitamin A, palmitate - 1080mcg, Vitamin B1 - 1.6mg, Vitamin B2 - 1.8mg, Vitamin B6 - 2.6mg, Vitamin B12 - 4mcg, Vitamin C - 100mg, Vitamin D3 - 12.5mcg, Vitamin E - 15mg, Biotin - 0.2mg, Calcium Pantothenate - 10mg, Folic acid - 0.8mg, Nicotinamide - 19mg, Calcium - 125mg, Magnesium - 100mg, Phosphorous - 125mg, Iron - 60mg, Copper - 1mg, Manganese - 1mg, Zinc - 7.5mg Tablet, film coated 893,655 L.L
D10AD51 ERYLIK G Tretinoin - 0.025%, Erythromycin - 4% Gel 374,932 L.L
L04AX04 ERVALI G Lenalidomide - 25mg 25mg Capsule, hard 81,147,769 L.L
L01EA02 ELPIDA G Dasatinib - 70mg 70mg Tablet, film coated 127,364,905 L.L
G04BE08 ENKOR G Tadalafil - 5mg 5mg Tablet, film coated 1,766,193 L.L
N06DA52 EXENTAZIL G Donepezil - 10mg, Memantine - 28mg Capsule 4,363,009 L.L
S01ED51 EPISOPT G Timolol - 5mg, Dorzolamide HCl - 20mg Drops 575,165 L.L
L01EA02 ELPIDA G Dasatinib - 50mg 50mg Tablet, film coated 127,364,905 L.L
N06DA52 EXENTAZIL G Donepezil - 10mg, Memantine - 14mg Capsule 3,117,715 L.L
    ...
    9
Sitemap
© Copyrights reserved to Ministry of Public Health 2026